Friedman-Eldar Orli, Zippel Douglas, Guy-Chen Helit, Eitan Gur Shlomi, Ben-Baruch Noa, Sharon Eran, Allweis Tanir M
Department of Surgery and Sarah Markowitz Breast Health Center, Kaplan Medical Center, Rehovot, Israel.
Meirav Breast Unit, Sheba Medical Center, Ramat-Gan, Israel.
Womens Health Rep (New Rochelle). 2020 Aug 31;1(1):301-307. doi: 10.1089/whr.2020.0044. eCollection 2020.
Advanced breast cancer (ABC) at diagnosis carries a worse prognosis, and can be attributed to delay in diagnosis, failure of screening tests, or aggressive biology. Better understanding of factors related with ABC at diagnosis could help decrease the proportion of such cases. This is a retrospective study of all patients diagnosed and treated for breast cancer (BC) at a single institution between 2012 and 2015. Data were collected from medical records and phone interviews, and included demographic, clinical, and tumor-related data, and adherence to screening recommendations. Of 555 newly diagnosed BC patients, 390 (70.3%) were diagnosed early (stage 0-IIa), and 165 (29.7%) were diagnosed with ABC (stage IIb-IV). Of the165 patients diagnosed with ABC, 57 (34.5%) underwent screening mammography as recommended. More patients with ABC were <50 years (29.1% vs. 19%, = 0.006). ABC was associated with higher grade, higher proliferation rate, Her2/neu overexpression, luminal B-like, and triple negative phenotypes. Mammography within 30 months of diagnosis was more prevalent among those diagnosed early (64.6% vs. 34.5%, = 0.003). Only 31 (18.8%) of the screening eligible patients who were diagnosed at advanced stage did not adhere to screening recommendations. ABC at diagnosis is related to aggressive tumor biology and age <50 years. It is also associated with lower adherence to screening mammography; however, more than one third of patients diagnosed with ABC who were eligible for screening underwent screening mammography as recommended. Further research is needed to elucidate factors related with ABC at diagnosis, review screening guidelines, and develop more effective screening modalities.
晚期乳腺癌(ABC)在确诊时预后较差,这可能归因于诊断延迟、筛查试验失败或侵袭性生物学行为。更好地了解与ABC确诊相关的因素有助于降低此类病例的比例。这是一项对2012年至2015年间在单一机构诊断和治疗的所有乳腺癌(BC)患者的回顾性研究。数据从病历和电话访谈中收集,包括人口统计学、临床和肿瘤相关数据以及对筛查建议的依从性。在555例新诊断的BC患者中,390例(70.3%)为早期诊断(0-IIa期),165例(29.7%)为ABC诊断(IIb-IV期)。在165例诊断为ABC的患者中,57例(34.5%)按建议进行了乳腺钼靶筛查。更多ABC患者年龄<50岁(29.1%对19%,P = 0.006)。ABC与更高分级、更高增殖率、Her2/neu过表达、管腔B样和三阴性表型相关。在诊断后30个月内进行乳腺钼靶检查在早期诊断患者中更为普遍(64.6%对34.5%,P = 0.003)。在晚期诊断的符合筛查条件的患者中,只有31例(18.8%)未遵循筛查建议。确诊时的ABC与侵袭性肿瘤生物学行为和年龄<50岁有关。它还与乳腺钼靶筛查的较低依从性相关;然而,超过三分之一符合筛查条件的ABC诊断患者按建议进行了乳腺钼靶筛查。需要进一步研究以阐明与ABC确诊相关的因素,审查筛查指南,并开发更有效的筛查方式。